Encyclopedia
Please note this is a comparison between Version 1 by Damien Vitiello and Version 3 by Dean Liu.
There is a clear impact of marathon on skeletal muscle and myocardium structure.
- cardiac fatigue
- cardiac stress
- prevention
- marathon
- recreational athletes
1. Introduction
The beneficial effect of regular physical exercise on heart function is now widely recognized by researchers in the field of physical activity and sport around the world and more generally in society. Among the main beneficial effects are the improvement of the lipid profile, carbohydrate homeostasis, decrease in resting blood pressure, blood coagulation, improvement of myocardial perfusion and an increase in cardiac output [1]. While the function of the heart pump is improved by regular exercise of moderate intensity [2], it was first shown in 1964 that the function of the left ventricle (LV) was reduced after prolonged physical exercise (PPE) [3]. Almost twenty years later, work has shown impaired cardiac function in athletes who have achieved PPE and used the concept of Exercise-Induced Cardiac Fatigue for the first time [4]. This phenomenon is defined as a transient decrease in systolic and diastolic ventricular functions and is sometimes associated with an increase in markers of myocardial degradation (i.e., cardiac troponins I) [5].
Endurance activities have been very popular since the end of the 1990′s. The attraction to life in the great outdoors and the desire to know its limits lead more and more people to practice PPE each year [6]. Among these PPE, there are those of moderate duration such as the half-marathon (i.e., between 1–2 h of effort) and the marathon (i.e., 2–4 h), those with long duration such as the semi-triathlon distance “Ironman” (i.e., 5–8 h), and the “Ironman” distance triathlon with its 3.8 km of swimming, 180 km of cycling and 42.195 km of running (i.e., 9–16 h) and those with very long duration such as ultra-marathons or ultra-trails (some events can exceed 24 h). The effect of these PPEs on the cardiac function of participants has been the subject of much scientific research since the end of the 1990′s. The general methodology used in these various works includes the evaluation of echocardiographic parameters of the cardiac function before and after PPE under resting conditions.
After a marathon running, the majority of studies have reported a decrease in LV and right ventricular (RV) diastolic function. Interestingly, the decrease in diastolic function was effective after 1 h of exercise [7]. More recently, it has been reported that cardiac fatigue is present but with left and right ventricular dysfunction, even more marked than at rest [8]. This study underlined the importance of the intensity of exertion during a marathon in the occurrence of cardiac fatigue. In summary, a moderate duration PPE results in a decrease in LV and RV diastolic function associated with a decrease in ventricular relaxation. The results concerning LV and RV systolic function are contradictory and seem to show that the myocardial alterations are rather dependent on the intensity with which the marathon is performed.
2. Biomarkers of Cardiac Fatigue and Cardiac Stress after a Marathon
Sixteen papers were identified in this review and are presented in Table 1. All of them were experimental studies and investigated the change in specific biomarkers between pre- and post-marathon runs. At least 32 different biomarkers were identified in the different studies. The majority of them were biomarker of skeletal muscle and myocardium damage [9][10][11][12][13][14][15][16][17][15,16,17,18,19,20,21,22,23]. In this family, the creatine kinase (CK), the highly sensitive cardiac troponin I and T (hs cTnI; hs cTnT) were mainly measured in the plasma. It was demonstrated that CK and hs cTnT were significantly increased after a marathon run. A second family of biomarkers measured the cardiac injury after marathons [18][11][12][13][15][17][19][20][9,17,18,19,21,23,24,25]. The N-terminal pro brain natriuretic peptide (NT-proBNP) was mainly measured in the plasma and was significantly increased after a marathon. In addition, it was reported that the increment of this biomarker immediately after a marathon exhibited a positive curvilinear relationship (r2 = 0.359, p = 0.023) with the running time achieved by the runners [20][25]. A third family of biomarkers measured the systemic inflammation after marathons [17][21][22][23,26,27]. The interleukin-6 (IL-6) and the tumor necrosis factor-alpha (TNF-alpha) were mainly measured in the plasma. It was demonstrated that both biomarkers were significantly increased after a marathon run.
Table 1. Cardiac fatigue, cardiac stress and marathon.
| References | Methods/Parameters | Pre-Marathon | Post-Marathon | p-Value |
|---|---|---|---|---|
| Biomarkers Analyses | ||||
| Traiperm [20] | ||||
| cTnT (ng/mL) | ||||
| NT-proBNP (pg/mL) | Curvilinear relationship between NT-ProBNP increment and running time (r2 = 0.359) | <0.05 | ||
| Kaleta-Duss [9] | ||||
| CK (U/l) | 148 ± 76.3 | 411 ± 170 | <0.001 | |
| hs-cTnI (ng/mL) | 0.01 ± 0.01 | 0.06 ± 0.09 | <0.001 | |
| H-FABP (ng/mL) | 2.22 ± 1.18 | 13.57 ± 9.63 | <0.001 | |
| BNP (pg/mL) | 79.86 ± 53.11 | 155.38 ± 156.23 | <0.001 | |
| NT-proANP (pg/mL) | 469.25 ± 155.44 | 753.3 ± 176.60 | <0.001 | |
| Gal-3 (ng/mL) | 8.53 ± 3.04 | 10.65 ± 2.33 | <0.001 | |
| GDF-15 (pg/mL) | 50.97 ± 27.61 | 137.34 ± 85.19 | <0.001 | |
| Martinez-Navarro [10] | ||||
| hs-cTnT (ng/L) | 5.74 ± 5.29 | 50.4 ± 57.04 | <0.001 | |
| Sierra [21] | ||||
| IL-6 (pg/mL) | 581 ± 1529 | 87 ± 53 | NS | |
| IL-8 (pg/mL) | 3099 ± 6511 | 1450 ± 6233 | NS | |
| IL-12p40 (pg/mL) | 3775 ± 12406 | 285 ± 131 | <0.05 | |
| IL-23 (pg/mL) | 3722 ± 12115 | 1004 ± 254 | <0.05 | |
| IL-33 (pg/mL) | 412 ± 1546 | 267 ± 145 | <0.05 | |
| TSLP (pg/mL) | 387 ± 1974 | 20 ± 16 | <0.05 | |
| eNO (ppb) | 20 ± 11 | 35 ± 19 | ↑ | |
| Wegberger [11] | ||||
| Troponin I (µg/L) | btw 0–0.01 | 0.03 (0.02–0.05) | 0.016 | |
| CK (U/L) | btw 0–250 | 425 (327–681) | 0.001 | |
| Copeptin (pmol/L) | btw 0–20 | 26.25 (16.29–39.02) | 0.078 | |
| NT-proBNP (ng/L) | btw 0–100 | 132 (64–198) | 0.001 | |
| MR-proADM (nmol/L) | btw 0.25–0.60 | 0.88 (0.55–0.99) | 0.023 | |
| de Gonzalo-Calvo [12] | ||||
| hs-cTnT (pg/mL) | btw 0–5 | btw 0–35 | <0.01 | |
| NT-proBNP (pg/mL) | btw 0–25 | btw 0–110 | <0.05 | |
| CK (U/L) | btw 0–150 | btw 0–300 | <0.001 | |
| hFABP (ng/mL) | btw 0–3 | btw 0–24 | <0.01 | |
| Gal-3 (ng/mL) | btw 0–7 | btw 0–22 | <0.001 | |
| Kosowski [13] | ||||
| hs-cTnI (pg/mL) | 3.67 (1.88–5.38) | 22 (9.58–34.56) | <0.001 | |
| NT-proBNP (pg/mL) | 50 (33–73) | 169 (112–365) | <0.001 | |
| ET-1 (pg/mL) | 3.03 (2.5–3.4) | 5.22 (4.4–5.89) | <0.001 | |
| Creatinine (mg/dL) | 0.85 (0.79–0.98) | 1.39 (1.22–1.56) | <0.001 | |
| Richardson [14] | ||||
| cTnT (ng/L) | 5.60 ± 3.27 | 74.52 ± 30.39 | <0.001 | |
| Sengupta [18] | ||||
| NT-proBNP (pg/mL) | 86.0 ± 9.5 | 106.5 ± 24.2 | 0.001 | |
| Clauss [19] | ||||
| Chromogranin A (pg/mL) | btw 0–60 | btw 0–90 | <0.001 | |
| NT-proBNP (ng/mL) | btw 0–30 | btw 0–110 | <0.001 | |
| Roca [15] | ||||
| NT-proBNP (ng/L) | 70 (70–70) | 92 (70–147) | <0.001 | |
| ST2 (ng/mL) | 34.2 (24.7–40.9) | 54.2 (38.2–72.4) | <0.001 | |
| hs-TnT (ng/L) | 2.9 (1.7–7) | 46.9 (24.1–91.1) | <0.001 | |
| Bekos [23] | ||||
| sRAGE (pg/mL) | btw 250–600 | btw 400–750 | <0.001 | |
| ST2 (pg/mL) | btw 0–250 | btw 125–400 | <0.001 | |
| Niemelä [22] | ||||
| suPAR (ng/mL) | btw 0.5–2 | btw 1.2–3.5 | <0.01 | |
| CD163 (ng/mL) | btw 300–800 | btw 500–1100 | <0.05 | |
| CRP (mg/L) | btw 0–12 | btw 0–22 | <0.05 | |
| IL-6 (pg/mL) | btw 0–8 | btw 17–25 | <0.01 | |
| IL-8 (pg/mL) | btw 5–12 | btw 25–42 | <0.05 | |
| IL-10 (pg/mL) | btw 0–1 | btw 1–3.5 | <0.05 | |
| TNF-α (pg/mL) | btw 0–1 | btw 1–2.5 | NS | |
| TGF-β (pg/mL) | btw 500–1000 | btw 0–1000 | NS | |
| Martin [16] | ||||
| Creatinine (mg/dL) | 0.94 ± 0.12 | 1.42 ± 0.24 | <0.001 | |
| CK (U/L) | 133 ± 60 | 367 ± 167 | <0.001 | |
| White blood cells (thousand/μL) | 5.75 ± 1.19 | 15.77 ± 3.29 | <0.001 | |
| Neutrophils (cells/μL) | 3420 ± 1049 | 13580 ± 3019 | <0.001 | |
| Scherr [17] | ||||
| hs-cTnT (ng/L) | 3 (3–5) | 31 (19–47) | <0.001 | |
| NT-proBNP (ng/L) | 27 (14–40) | 93 (57–150) | <0.001 | |
| h-FABP (Kg/L) | 7 (5–10) | 45 (32–64) | <0.001 | |
| hs-CRP (mg/L) | 0.52 (0.30–0.93) | 0.40 (0.24–0.85) | <0.001 | |
| IL-6 (ng/L) | 2.1 (1.9–2.2) | 32 (21–41) | <0.001 | |
| IL-10 (ng/L) | 5.1 (4.9–5.4) | 20 (11–50) | <0.001 | |
| TNF-α (ng/L) | 9 (7–10) | 10 (9–12) | <0.001 | |
| Cystatin C (mg/L) | 0.8 (0.7–0.9) | 0.9 (0.9–1.0) | <0.001 | |
| Baggish [24] | ||||
| c-miR-1 (fold change) | 21.8 | 0.04 | ||
| c-miR-126 (fold change) | 1.9 | <0.001 | ||
| c-miR-133 (fold change) | 18.5 | 0.02 | ||
| c-miR-134 (fold change) | 1.9 | <0.001 | ||
| c-miR-146a (fold change) | 3.3 | <0.001 | ||
| hsCRP (fold change) | 1.0 | 1.000 | ||
| Echography, HRV & STE analyses | ||||
| Lewicka-Potocka [25] | ||||
| LV EF (%) | 61.8 ± 4.9 | 60.5 ± 4.4 | 0.38 | |
| LV GLS (%) | −19.9 ± 2.3 | −19.4 ± 2.1 | 0.41 | |
| RV 4CSL (%) | −22.0 ± 2.8 | −20.80 ± 2.6 | <0.05 | |
| TAPSE (mm) | 25.0 ± 3.6 | 24.0 ± 3.7 | 0.56 | |
| RVd MID (cm) | 3.4 ± 0.6 | 3.7 ± 0.5 | <0.01 | |
| RVd BAS (cm) | 3.8 ± 0.4 | 3.8 ± 0.5 | 0.44 | |
| LVd BAS (cm) | 4.8 ± 0.4 | 4.6 ± 0.3 | <0.001 | |
| RVd/LVd BAS | 0.77 ± 0.1 | 0.82 ± 0.1 | <0.05 | |
| Roeh [26] | ||||
| E/A | 1.6 ± 0.5 | 1.1 ± 0.3 | <0.001 | |
| E/e’ mean | 6.4 ± 1.5 | 6.5 ± 1.8 | 0.6 | |
| DT (s) | 0.18 ± 0.05 | 0.20 ± 0.05 | <0.001 | |
| Vmin (mL/m2) | 11.4 ± 3.7 | 9.9 ± 3.5 | <0.01 | |
| Vmax (mL/m2) | 28.0 ± 6.2 | 25.0 ± 7.0 | <0.01 | |
| Total-SV (mL/m2) | 59.6 ± 7.8 | 60.7 ± 6.0 | 0.3 | |
| Total-EF (%) | 34.9 ± 8.6 | 31.33 ± 10.2 | <0.01 | |
| ASV (mL/m2) | 16.6 ± 3.8 | 15.1 ± 4.1 | <0.01 | |
| True-EF (%) | 6.1 ± 2.4 | 4.8 ± 2.8 | <0.001 | |
| Sengupta [18] | ||||
| Heart rate (beats/minute) | 74.1 ± 6.4 | 64.5 ± 7.6 | <0.001 | |
| Systolic BP (mmHg) | 123 ± 11 | 120 ± 9 | 0.214 | |
| Diastolic BP (mmHg) | 79 ± 5 | 79 ± 5 | 0.675 | |
| IVSd (cm) | 0.94 ± 0.16 | 1.03 ± 0.20 | 0.005 | |
| LV mass (gm) | 0.94 ± 0.16 | 1.03 ± 0.20 | 0.005 | |
| LV mass (gm) | 120.2 ± 30.0 | 160.3 ± 43.0 | <0.001 | |
| LVEDV (mL) | 61.8 ± 16.5 | 72.8 ± 5.1 | <0.001 | |
| LVESV (mL) | 21.9 ± 7.5 | 20.3 ± 3.7 | 0.191 | |
| LVEF (%) | 64.9 ± 5.6 | 72.0 ± 5.7 | <0.001 | |
| Mitral E (cm/s) | 89.8 ± 17.1 | 80.1 ± 17.0 | 0.001 | |
| Mitral annular e0 (cm/s) | 10.4 ± 2.1 | 10.1 ± 2.2 | 0.638 | |
| Mitral E/e0 | 9.1 ± 2.4 | 8.3 ± 2.7 | 0.227 | |
| Left atrial volume index (mL/m2) | 23.2 ± 6.1 | 19.0 ± 6.5 | 0.01 | |
| LV global longitudinal strain (%) | −19.3 ± 2.71 | −16.5 ± 4.6 | 0.003 | |
| LV global circumferential strain (%) | −17.2 ± 2.41 | −15.2 ± 2.6 | 0.001 | |
| LV global radial strain (%) | 31.9 ± 7.4 | 30.9 ± 1.3 | 0.422 | |
| Mertová [27] | ||||
| Sympathovagal balance | - | Ln LF/HF | ↑ | |
| Heart rate (bpm) | - | +30 | ||
| Sierra [28] | ||||
| Peak VO2 (mL/kg/min) | 51 (46–52) | 46 (43–49) | <0.05 | |
| Peak VE (L/min) | 134 (99–148) | 120 (111–147) | NS | |
| VE/VCO2 slope | 34 (30–41) | 31 (27–39) | <0.05 | |
| HR | 62 (60–67) | 104 (101–111) | <0.05 | |
| Systolic volume | 80 (79–100) | 61 (51–68) | <0.05 | |
| Cardiac output | 5354(4747–6458) | 6234(5238–7433) | NS | |
| LVEDD | 51(49–52) | 51 (45–58) | NS | |
| LVESD | 32 (29–32) | 32 (28–34) | NS | |
| EF | 67 (66–70) | 62 (61–67) | NS | |
| E wave | 0.9 (0.7–1.0) | 0.6 (0.5–0.7) | <0.05 | |
| A wave | 0.7 (0.5–0.9) | 0.9 (0.8–0.9) | NS | |
| E/A ratio | 1.3 (1.1–1.5) | 0.7 (0.6–0.8) | <0.05 | |
| s’ wave | 8.8 (8.2–9.7) | 6.7 (5.9–8.0) | <0.05 | |
| e’ wave | 9.2 (8.4–10.6) | 8.5 (6.4–10.4) | NS | |
| a’ wave | 8.1 (7.6–9.1) | 7.6 (6.6–9.6) | NS | |
| E/e’ ratio | 0.09 (0.08–0.10) | 0.08 (0.06–0.09) | NS | |
| Hanssen [29] | ||||
| Heart rate (beats/min) | 57 ± 7 | 86 ± 13 | <0.001 | |
| Systolic blood pressure (mmHg) | 132 ±13 | 121 ± 12 | <0.001 | |
| Diastolic blood pressure (mmHg) | 86 ± 8 | 74 ± 7 | <0.001 | |
| LVEF (%) | 65 ± 4 | 67 ± 5 | 0.280 | |
| LV end-diastolic volume (cm3) | 120 ± 25 | 113 ± 27 | 0.142 | |
| E (cm/s) | 74 ± 14 | 66 ± 14 | 0.054 | |
| A (cm/s) | 56 ± 13 | 72 ± 12 | <0.001 | |
| E /A ratio | 1.4 ± 0.3 | 0.9 ± 0.2 | <0.001 | |
| Septal E’ (cm/s) | 10 ± 1 | 8 ± 2 | 0.001 | |
| Septal A’ (cm/s) | 10 ± 2 | 12 ± 3 | 0.001 | |
| E /E’ ratio | 8.3 ± 1.6 | 8.4 ± 3.4 | 0.871 | |
| Chan-Dewar [30] | ||||
| Sub-epicardial radial strain (%) |
32.6 ± 12.5 | 20.3 ± 9.6% | <0.01 | |
| Sub-endocardial circumferential strain (%) | −26.9 ± 3.6 | −23.7 ± 4.1 | <0.01 | |
| EF | 63 ± 5 | 62 ± 7 | NS | |
| E/A | 1.8 ± 0.7 | 1.1 ± 0.2 | <0.01 |
4CSL: four-chamber longitudinal strain = global strain; ASV: atrial stroke volume; BNP: B-type natriuretic peptide; BP: blood pressure; Bpm: beats per minutes; Btw: between; CK: creatine kinase; DT: deceleration time; E: early diastolic mitral inflow velocity; E/e’: ratio of early diastolic mitral inflow to mitral annular velocity; e’: early diastolic mitral annular velocity; EDD: end-diastolic diameter; EF: ejection fraction; eNo: exhaled nitric oxide; ESD: end-systolic diameter; ESV: end-systolic volume; FAC: fractional area change; Gal-3: galectin 3; GDF-15: growth differentiation factor 15; GLS: global longitudinal strain; H-FABP: heart-type fatty acid binding protein; HRV: heart rate variability; hs-cTnI: high sensitivity cardiac troponin I; IL: interleukin; IVSd: diastolic interventricular septum thickness; LF/HF: low-frequency power/high-frequency power; LV: left ventricle; LVd BAS: LV basal end-diastolic diameter; LVEDD: left ventricular end-diastolic diameter; LVEDV: left ventricular end-diastolic volume; LVEF: left ventricular ejection fraction; LVESD: left ventricular end-systolic diameter; LVESV: left ventricular end-systolic volume; NT-proANP: N-terminal proatrial natriuretic peptide; PWd: posterior wall in diastole; PWs: posterior wall in systole; RV: right ventricle; RVd BAS: RV basal end-diastolic diameter; RVd MID: RV mid-cavity end-diastolic dimension; RVd/LVd BAS: basal RV to LV end-diastolic diameter ratio; S: peak systolic pulmonary venous flow velocity; STE: speckle tracking echography; SV: stroke volume; TAPSE: tricuspid annular plane systolic excursion; Total-EF: total ejection fraction; Total-SV: total stroke volume; True-EF: true ejection fraction. Data are expressed as means, medians and interquartile ranges (25th percentile; 75th percentile) and R-squared.
4CSL: four-chamber longitudinal strain = global strain; ASV: atrial stroke volume; BNP: B-type natriuretic peptide; BP: blood pressure; Bpm: beats per minutes; Btw: between; CK: creatine kinase; DT: deceleration time; E: early diastolic mitral inflow velocity; E/e’: ratio of early diastolic mitral inflow to mitral annular velocity; e’: early diastolic mitral annular velocity; EDD: end-diastolic diameter; EF: ejection fraction; eNo: exhaled nitric oxide; ESD: end-systolic diameter; ESV: end-systolic volume; FAC: fractional area change; Gal-3: galectin 3; GDF-15: growth differentiation factor 15; GLS: global longitudinal strain; H-FABP: heart-type fatty acid binding protein; HRV: heart rate variability; hs-cTnI: high sensitivity cardiac troponin I; IL: interleukin; IVSd: diastolic interventricular septum thickness; LF/HF: low-frequency power/high-frequency power; LV: left ventricle; LVd BAS: LV basal end-diastolic diameter; LVEDD: left ventricular end-diastolic diameter; LVEDV: left ventricular end-diastolic volume; LVEF: left ventricular ejection fraction; LVESD: left ventricular end-systolic diameter; LVESV: left ventricular end-systolic volume; NT-proANP: N-terminal proatrial natriuretic peptide; PWd: posterior wall in diastole; PWs: posterior wall in systole; RV: right ventricle; RVd BAS: RV basal end-diastolic diameter; RVd MID: RV mid-cavity end-diastolic dimension; RVd/LVd BAS: basal RV to LV end-diastolic diameter ratio; S: peak systolic pulmonary venous flow velocity; STE: speckle tracking echography; SV: stroke volume; TAPSE: tricuspid annular plane systolic excursion; Total-EF: total ejection fraction; Total-SV: total stroke volume; True-EF: true ejection fraction. Data are expressed as means, medians and interquartile ranges (25th percentile; 75th percentile) and R-squared.
Three of the selected studies measured the heart-type fatty acid binding protein (H-FABP) (i.e., mainly found inside cardiomyocytes) after a marathon [9][12][17][15,18,23]. Despite an important variability between the studies, H-FABP was significantly increased after a marathon run in three studies.
In addition, two studies measured the galactin-3 (gal-3) which is a protein involved in various biological activities in different organs, including apoptotic regulation, inflammation and fibrosis [9][12][15,18]. After a marathon, this protein was significantly increased in both studies. Another two studies measured the suppression of tumorigenicity 2 (ST2) [15][23][21,28] after a marathon. They both reported a significant increase of ST2 after running. Technical issues and determination of a diagnostic threshold have to be done to fully recognize the specificity of these biomarkers.
Finally, only one study investigated the potential of circulating short nonprotein coding RNA (c-miRNA) to explore the impact of a marathon run [24][29]. In this study, which was conducted with 21 healthy male marathon runners, the authors demonstrated that all plasma levels of the selected c-miRNA (i.e., enriched in muscle: c-miR-1; c-miR-133a; c-miR-499-5p; enriched in myocardium: c-miR-208a; enriched in vascular endothelium: c-miR-126; marker of inflammation: c-miR-146a) were significantly increased when compared to pre-marathon. The authors also stated that these c-miRNAs might represent real-time and tissue-specific adaptation biomarkers of a marathon run.
34. Cardiovascular Function after Marathon
Seven papers were identified in this review and are presented in Table 1. All of them were experimental studies and assessed the cardiovascular function before and after a marathon run. The majority of the selected studies used echocardiography alone [18][25][26][28][30][9,30,31,33,35]. The majority of these studies reported a decreased E wave and/or an E/A ratio after a marathon. They also all reported no significant difference of the LV EF values between pre- and post-marathon. Three of these studies used the speckle tracking imaging technique to evaluate LV and RV strains [18][25][30][9,30,35]. For LV function, Sengupta et al. reported a significant decrease of the global longitudinal (≈−3% in average) and circumferential (−2% in average) strains but not in the radial plane after a marathon in recreational runners with a mean age of 41 ± 8 years [18][9]. In their study, Chan-Dewar et al. reported a significant decrease of the LV subepicardial radial strain (−12.3% in average) sub-endocardial circumferential strain (−3.2% in average) in male non-elite marathon runners with a mean age of 32 ± 10 years [30][35]. On the contrary, Lewika-Potocka et al. did not report any difference for the LV global strain between pre- and post-marathon in amateur marathon runners with a mean age of 40 ± 8 years [25][30]. However, these authors also analyzed the RV function and they reported a significant decrease of the RV four chambers longitudinal strain after a marathon (−1.2% in average).
Moreover, one study used the heart rate variability to assess the cardiac autonomous nervous system [27][32] and one study assessed cardiac function with cardiac magnetic resonance and echocardiography [29][34], pre- and post-marathon. In the first study, the authors reported a significant increase of the cardiac sympathetic activity (+30 min) and of the heart rate in supine position (+30 bpm) after a skyrunning marathon (i.e., 42 km distance with an ascent distance of 3.15 km and a descent distance of 2.85 km) in healthy male amateurs with a mean age of 37 ± 9 years. In the second study, the authors demonstrated a significant decrease of the LV E/A ratio and of the LV septal E’ and A’ waves after a marathon with male amateur runners with a mean age of 41 ± 5 years. In addition, they demonstrated no difference between pre- and post-marathon for the LV radial shortening and the circumferential and longitudinal strains assessed by MRI. However, the analysis revealed an increase in LV torsion and maximal torsion velocity after a marathon.
